GlaxoSmithKline CEO and CFO Interviewed on Q2 2011 Results

By Glaxosmithkline, PRNE
Monday, July 25, 2011

LONDON, July 26, 2011 -

UK pharma group GlaxoSmithKline reports a 2% sales dip in the second quarter but highlights strong underlying sales momentum.

In an interview with financial broadcaster www.cantos.com, CEO Andrew Witty and CFO Simon Dingemans review Q2 results including overall delivery of strategy, declining “headwinds”, R&D strategy, improving margins and a review of the recently implemented Drug Performance Units.

The interview and transcript are available now on www.cantos.com/company/GlaxoSmithKline.

Cantos.com, the online financial broadcaster, features in-depth interviews, documentaries and webcasts with senior company executives. If you would like to contact us, please email prnsupport@cantos.com or phone +44-207-936-1352.